Status:
UNKNOWN
A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device
Lead Sponsor:
Kaligia Biosciences, LLC
Collaborating Sponsors:
University of South Florida
Conditions:
Coronavirus
COVID
Eligibility:
All Genders
18+ years
Brief Summary
The current available diagnostic methods used for the detection of COVID-19 takes up to 4 hours. In some cases, these diagnostics tests make take up to a couple of days. As it is highly contagious, pe...
Detailed Description
The purpose of this study is to calibrate the performance of RBA-2 using people by comparing the results against a standard diagnostics test. The objective of this study is to collect non-invasive in ...
Eligibility Criteria
Inclusion
- Participants can be patients or staff members at the testing site.
- Potential participants may be enrolled if:
- They are identified as requiring a standard diagnostic test for COVID-19 or are being treated after testing positive for COVID-19;
- They are age ≥ 18 years old;
- They are willing and able to provide verbal informed consent.
Exclusion
- Patients receiving active treatment with antivirals, chloroquine or immune modulators.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04357977
Start Date
April 1 2020
End Date
December 1 2020
Last Update
April 22 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampa General Hospital
Tampa, Florida, United States, 33606
2
University of South Florida
Tampa, Florida, United States, 33612
3
AdventHealth Tampa
Tampa, Florida, United States, 33613